Please ensure Javascript is enabled for purposes of website accessibility

Why Humanigen Stock Is Down Today

By Prosper Junior Bakiny - Jan 20, 2021 at 12:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced an important change to one of its ongoing clinical trials.

What happened?

Shares of Humanigen (HGEN 0.89%) were down by 8.6% as of 12:50 p.m. EST Wednesday, after having fallen by as much as 13% earlier in the trading day. The catalyst for these losses seems to be an update the clinical-stage biopharmaceutical company delivered regarding its phase 3 clinical trial for lenzilumab in patients hospitalized with COVID-19. 

So what

The phase 3 study in question originally started in late April 2020, and its primary endpoint was time to recovery for coronavirus patients. In a regulatory filing submitted Tuesday night, Humanigen said it was changing the primary endpoint to ventilator-free survival through day 28. Time to recovery will now be one of the study's secondary endpoints.

Sheet of paper on a clipboard with the word "coronavirus" written on it.

Image source: Getty Images.

According to healthcare company, "this change in the primary endpoint represents a more meaningful endpoint for patients, health-care providers, and payors given the current standard of care for hospitalized and hypoxic COVID-19 patients." Naturally, Humanigen had to discuss these changes with the U.S. Food and Drug Administration before moving forward. The company also noted that as of Tuesday, more than 500 patients had been enrolled in the study.

Now what

Humanigen has a lot riding on this clinical trial. The company's shares are up by more than 900% in the past 12 months, in parts thanks to its coronavirus-related efforts. And despite the fact that investors are not thrilled with the protocol change, lenzilumab has already shown some success in treating COVID-19 patients. In other words, it might be worth it to keep an eye on Humanigen. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Humanigen, Inc. Stock Quote
Humanigen, Inc.
$2.26 (0.89%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.